Highlights

Share

Program Content

Activities

  • New Data From AIDS 2018
    Clinical Impact of New Data From AIDS 2018
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 09, 2018

    Expires: August 08, 2019

Activities

E/C/F/TAF and M184V/I
Study 1824: Virologic Suppression Maintained in Patients With M184V/I Mutation After Switch to EVG/COBI/FTC/TAF
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2018

DRIVE-FORWARD: Week 96 Follow-up
DRIVE-FORWARD: Durable Virologic Efficacy With Doravirine Plus NRTIs vs Darunavir/Ritonavir Plus NRTIs Through Week 96 in ART-Naive Patients
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 25, 2018

GEMINI-1 and -2
GEMINI-1 and -2: Dual-Therapy With DTG Plus 3TC Noninferior to DTG Plus FTC/TDF in Treatment-Naive Patients at Week 48
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2018

PARTNER2
PARTNER2: Risk of HIV Transmission From HIV-Positive Partner on Suppressive ART Is Effectively Zero for MSM
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2018

Tsepamo: DTG and Neural Tube Defects
Tsepamo: Preliminary Data Suggest Increased Risk of Neural Tube Defects With Dolutegravir Exposure at Conception
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2018

Prevenir Interim Analysis
Prevenir: Interim Analysis Shows High Efficacy of Daily or On-Demand PrEP Among MSM
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2018

BRIGHTE Subgroup Analysis
BRIGHTE: Fostemsavir Plus OBT Associated With Similar Virologic Efficacy in Most Subgroups of Heavily Treatment–Experienced Patients at Week 24
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 30, 2018

SWORD-1, -2: Week 100 Follow-up
SWORD-1 and -2: Durable Virologic Efficacy Through Week 100 With Switch From Baseline ART to DTG Plus RPV in Virologically Suppressed Patients
Capsule Summary
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 31, 2018

Faculty

cover img faculity

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom

Provided by

ProCE Banner

Supporters

Janssen

ViiV Healthcare

Partners

AIDS 2018

ProCE Banner

IAS 2018

ProCE Banner